GPIb.alpha. fragments and recombinant DNA expression vectors |
| As set forth in aforementioned application Ser. No. 07/470,674, there are provided peptides ... |
|
Expression vector encoding hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
Hybrid immunoglobulins |
| Ligand binding partners as defined herein are proteins known to function to bind specifically to ... |
|
GPIb-lipid complex and uses thereof |
| What is claimed is: 1. A complex comprising a lipid and a conjugate of GPIb or a GPIB fragment ... |
|
Immuno-modulating antitumor activities of Ganoderma lucidum (Reishi) polysaccharides |
| We claim: 1. A composition comprising one or more fractions, the one or more fractions obtainable ... |
|
Painless electrolyte solutions |
| What is claimed is: 1. A composition consisting of: (a) electrolytes selected from the group ... |
|
Method for enhancing healing of corneal endothelial wounds |
| Method using a non-steroidal antiinflammatory compound, such as indomethacin, and/or a growth ... |
|
Method and agents for promoting wound healing |
| In accordance with the present invention, diagnostic and therapeutic protocols are proposed that ... |
|
Control of post-surgical intraocular pressure using clonidine derivatives |
| OF THE INVENTION The present invention utilizes certain clonidine derivatives, as defined above, ... |
|
|
Semi-refined carrageenan
| Details |
Inventors: Tsai, Albert G.; Ledwith, Linnea K.; Kopesky, Robert; Lynch, Maurice Gerard; Blakemore, William Ross; Riley, Peter J.;
Assignee: FMC Corporation (Philadelphia, PA)
Primary Examiner: Gitomer; Ralph
Assistant Examiner:
Attorney, Agent or Firm: RatnerPrestia
The Methods of the present invention prepare carrageenan products from processed seaweed material using shear stress treatment are disclosed. The carrageenan products comprise at least about 65% by weight of carrageenan and at least about 2% by weight of acid insoluble material. The carrageenan products of the present invention preferably have an onset of hydration below about 40° C. and a color of greater than about 74 *L units. The carrageenan products of the present invention are useful as components in food products, such as, dairy products, meats, and dessert gels as well as non-food products, such as, toothpaste formulations, cosmetics, and paints. |
|
DETAILED DESCRIPTION The present invention provides methods for preparing a carrageenan product comprising the steps of providing a carrageenan-containing seaweed material having a seaweed solids content of less than 25% by weight, and subjecting this seaweed material to shear stress treatment. The carrageenan-containing seaweed material optionally is treated with base prior to extrusion. In one embodiment, the carrageenan-containing seaweed material is prepared by a process comprising the steps of washing the seaweed with water to produce washed seaweed; rinsing the seaweed with water to form rinsed seaweed; and washing the rinsed seaweed with water or an aqueous solution to form the carrageenan-containing seaweed material. In another embodiment, the methods of the present invention comprise washing the seaweed with water; treating the seaweed with a base at a temperature of about 25° C. to about 65° C. to form base-modified seaweed; rinsing the base-modified seaweed with water; washing this base-modified seaweed with an aqueous solution of a salt; rinsing this base-modified seaweed with water to form processed seaweed, wherein the processed seaweed comprises less than 25% solids; extruding this processed seaweed to form extruded seaweed; and drying the extruded seaweed to form a carrageenan product. In yet another embodiment, the concentration of the aqueous salt solution is less than about 40%. It is preferred that the concentration of the aqueous salt solution be less than about 15%. It is more preferred that the concentration of the aqueous salt solution be between about 2% and about 15%. The present invention also includes carrageenan products that preferably comprise at least about 60% by weight of carrageenan and at least about 2% by weight of acid insoluble material, and have an onset of hydration below about 50° C. In a preferred embodiment, the carrageenan product is derived from Eucheuma spinosum, or any other species containing iota-carrageenan. In another preferred embodiment, the carrageenan product further comprises about 2% to about 15% by weight of a salt
|
| Related patents |
|
|
Method for improving genetic stability of foreign insert nucleotide sequence in recombinant poliovirus
To be free from shortcomings of the poliovirus vector systems, in particular, genetic instability of the foreign insert integrated into the recombinant polioviruses, the ...
|
|
|
Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
The invention relates to adult dedifferentiated programmable stem cells derived from human monocytes, as well as their production and use for the production of body ...
|
|
|
Peptides which enhance transport across tissues and methods of identifying and using the same
The invention provides a method of identifying a peptide which permits or facilitates the transport of an active agent through a human or animal tissue. A predetermined ...
|
|
|
Synthetic peptides and kits for diagnosis of anti-phospholipid syndrome
The invention claimed is: 1. A synthetic peptide selected from the group consisting: (i) a peptide of SEQ ID NO:1 to SEQ ID NO: 7, of the sequences: Leu-Lys-Thr-Pro-Arg-V...
|
|
|
Synthetic peptide inhibitors of HIV transmission
OF THE INVENTION 5.1 DP-178 AND DP-178-LIKE PEPTIDES 5.2 ASSAYS FOR ANTIVIRAL ACTIVITY 5.3 USES OF THE PEPTIDES OF THE INVENTION 6. EXAMPLE: DP-178 (SEQ ID:1) IS A POTEN...
|
|
|
Compounds which inhibit HIV replication
A first aspect of the present invention is a peptide selected from the group consisting of: (a) the peptide DP-107, which has the formula, from amino terminus to carboxy ...
|
|
|
Hybrid polypeptides with enhanced pharmacokinetic properties
OF THE INVENTION Described herein are peptide sequences, referred to as enhancer peptide sequences, derived from various retroviral envelope (gp41) protein sequences ...
|
|
|
1-aryl-2-hydroxyethyl amides as potassium channel openers
OF THE INVENTION The present invention provides novel aryl hydroxyethyl amides and related derivatives which are modulators of the KCNQ potassium channels and which ...
|
|
|
Method of eliciting anti-HIV-1 helper T cell responses
A number of HIV-1 p24 peptides that elicit HIV-1-specific helper T cell responses have been identified. Contemplated within the scope of this invention are methods of ...
|
|
|
pDJA1, a cardiac specific gene, corresponding proteins, and uses thereof
OF THE INVENTION Before the present methods and treatment methodology are described, it is to be understood that this invention is not limited to particular methods, ...
|
|
|